The European Commission has approved Novo Holdings A/S’ acquisition of Catalent, Inc., a global contract development and manufacturing organization headquartered in New Jersey, as well as Novo Nordisk’s subsequent acquisition of three manufacturing sites from Novo Holdings A/S.
 
The industry has been closely monitoring the situation between Novo Nordisk and Catalent since its announcement earlier this year. Catalent is a leading provider of outsourcing services, offering expertise to numerous clients as their contracted supplier. Therefore, this news is significant, as stakeholders are eager to learn how Novo Nordisk’s acquisition of Catalent may impact its relationships with these clients over time.
 
In a recent open letter to customers, President and Chief Executive Officer of Catalent, Alessandro Maselli, promised Catalent will continue to operate as a global, independent, full-service CDMO under Novo Holdings’ ownership.
 
The agreement to acquire the three manufacturing sites was announced in February 2024.
 
On May 29, 2024, Catalent stockholders voted to approve the pending transaction. Additionally, the acquisition has been approved by the authorities in a number of jurisdictions.
 
The completion of the acquisition remains subject to the fulfillment of further customary closing conditions, including regulatory approvals in other jurisdictions. Novo Nordisk still expects the acquisition to be completed towards the end of 2024.